Inegy

Simvastatin/Ezetimibe, the active ingredients in Inegy, are HMG‑CoA reductase inhibitor and cholesterol absorption inhibitor presented as a tablet for oral use. They lower elevated cholesterol levels in adults with hypercholesterolemia or mixed dyslipidemia. GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inegy is indicated for lipid disorders and works to improve cholesterol profiles in several conditions.

Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol levels. Mixed dyslipidemia: improves overall lipid profile by lowering LDL and triglycerides while raising HDL. Heterozygous familial hypercholesterolemia: provides additional LDL‑C reduction when diet and lifestyle alone are insufficient.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Abdominal pain: discomfort in the stomach area. - Diarrhea: loose stools occurring intermittently. - Nausea: feeling of sickness or urge to vomit. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible kidney injury. - Hepatic failure: signs of liver dysfunction such as jaundice. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Pancreatitis: acute abdominal pain with elevated enzymes. - Myopathy with marked CK elevation: muscle weakness with high creatine kinase. - Interstitial lung disease: rare respiratory symptoms and imaging changes.

Before initiating therapy, consider the following precautions.

Liver function monitoring: obtain baseline tests and repeat periodically. Muscle symptom assessment: discontinue if severe myopathy or rhabdomyolysis is suspected. Active liver disease: avoid use in patients with known hepatic impairment. CYP3A4 inhibitors: adjust dose or avoid concomitant strong inhibitors. Pregnancy and lactation: safety not established; use only if clearly needed. Store at room temperature: keep in the original container, protect from moisture and light.

Inegy may interact with several drug classes; review patient medication lists.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase statin exposure. - Gemfibrozil: markedly raises risk of myopathy. - Cyclosporine: elevates plasma concentrations of both components. - High‑dose niacin: potentiates muscle toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Digoxin: possible increase in serum levels. - Other fibrates (except gemfibrozil): monitor for muscle effects. - Antacids: may reduce ezetimibe absorption; separate administration times. - Amiodarone: modest increase in statin levels, observe for muscle symptoms.